ESMO: Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR inhibitors derazantinib and erdafitinib : an analysis in safety relevant normal tissues from urothelial cancer (UC) patient derived mouse xenograft (PDX) models Date Published: View Poster: https://www.annalsofoncology.org/article/S0923-7534(20)41348-1/fulltext
